Blog | Skyhawk Therapeutics

Careers

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR® platform.SKY-0515’s Phase 1 study will inc

Drugging RNA

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success. Companies differ...

Drugging RNA with Pills : Small Molecules for a Big Frontier

Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets? Infused...

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

Paul Schloesser – Associate Editor, Endpoints A heavily financed biotech looking to drug RNA with small molecules is adding yet another...

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Nicole DeFeudis – Editor, Endpoints A few years after becoming one of the first major biotechs out to drug RNA with small molecules,...

Skyhawk Therapeutics Completes New Investment Round

WALTHAM, MA— Sep 14, 2021 /PRNewswire/— A $133 million round of investment will allow Skyhawk to accelerate development of its novel...

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and ...

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical...

$40M up front: Skyhawk takes flight with Vertex deal

Skyhawk Therapeutics Inc., one of the early leaders in developing small-molecule drugs that target RNA, closed out the year with yet...

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

by Nick Paul Taylor | Vertex will take full responsibility for development and commercialization of assets it licenses from Skyhawk...

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh discovery effort John Carroll – Editor &...

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them John Carroll : Editor &...

Skyhawk News